| Bioactivity | Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50 of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities[1]. | ||||||||||||
| Invitro | Delanzomib (CEP-18770; 20 nM; 12-24 hours) treatment results in a progressive appearance of cleaved caspases-3, -7, and -9 between 12 and 24 hours’exposure in the human MM cell lines, RPMI-8226, and U266[1].Delanzomib (CEP-18770; 5-40 nM; 4-24 hours) treatment induces an accumulation of ubiquitinated proteins over 4 to 8 hours[1].Delanzomib (CEP-18770) inhibits endothelial cell survival, vasculogenesis, and osteoclastogenesis in vitro; and displays a favorable cytotoxicity profile toward normal cells[1]. Apoptosis Analysis[1] Cell Line: | ||||||||||||
| Name | Delanzomib | ||||||||||||
| CAS | 847499-27-8 | ||||||||||||
| Formula | C21H28BN3O5 | ||||||||||||
| Molar Mass | 413.28 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Delanzomib
CAS: 847499-27-8 F: C21H28BN3O5 W: 413.28
Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.